CXCL4 in atherosclerosis: Possible roles in monocyte arrest and macrophage foam cell formation (original) (raw)

Thromb Haemost 2007; 98(05): 917-918
DOI: 10.1160/TH07-09-0567

Schattauer GmbH

Authors

• Christian A. Gleissner *
  1Department of Biomedical Engineering, University of Virginia, Charlottesville, Virginia, USA
  3Robert M. Berne Cardiovascular Research Center, University of Virginia, Charlottesville, Virginia, USA
• Klaus Ley *
  1Department of Biomedical Engineering, University of Virginia, Charlottesville, Virginia, USA
  2Department of Molecular Physiology and Biological Physics, University of Virginia, Charlottesville, Virginia, USA
  3Robert M. Berne Cardiovascular Research Center, University of Virginia, Charlottesville, Virginia, USA

Financial support: This work was supported by the Deutsche Forschungsgemeinschaft (grant GL599/1–1 to C.A.G.) and by NIH grant HL58108 (to K.L.).

Further Information

Publication History

Received 19 September 2007

Accepted 19 September 2007

Publication Date:
30 November 2017 (online)

* After November 1, 2007 Division of Inflammation Biology, La Jolla Institute for Allergy & Immunology, La Jolla, CA, USA.

• References

• 1 Sachais BS, Turrentine T, Dawicki McKenna JM. et al. Elimination of platelet factor 4 (PF4) from platelets reduces atherosclerosis in c57bl/6 and apoE-/- mice. Thromb Haemost 2007; 98: 1108-1113.
• 2 Deuel TF, Keim PS, Farmer M. et al. Amino acid sequence of human platelet factor 4. Proc Natl Acad Sci USA 1977; 74: 2256-2258.
• 3 Massberg S, Schulz C, Gawaz M. Role of platelets in the pathophysiology of acute coronary syndrome. Semin Vasc Med 2003; 3: 147-162.
• 4 Huo Y, Schober A, Forlow SB. et al. Circulating activated platelets exacerbate atherosclerosis in mice deficient in apolipoprotein E. Nat Med 2003; 9: 61-67.
• 5 von Hundelshausen P, Weber KS, Huo Y. et al. RANTES deposition by platelets triggers monocyte arrest on inflamed and atherosclerotic endothelium. Circulation 2001; 103: 1772-1777.
• 6 Pitsilos S, Hunt J, Mohler ER. et al. Platelet factor 4 localization in carotid atherosclerotic plaques: Correlation with clinical parameters. Thromb Haemost 2003; 90: 1112-1120.
• 7 von Hundelshausen P, Petersen F, Brandt E. Platelet- derived chemokines in vascular biology. Thromb Haemost 2007; 97: 704-713.
• 8 Ley K, Laudanna C, Cybulsky MI. et al. Getting to the site of inflammation: The leukocyte adhesion cascade updated. Nat Rev Immunol 2007; 7: 678-689.
• 9 von Hundelshausen P, Koenen RR, Sack M. et al. Heterophilic interactions of platelet factor 4 and RANTES promote monocyte arrest on endothelium. Blood 2005; 105: 924-930.
• 10 Scheuerer B, Ernst M, Durrbaum-Landmann I. et al. The CXC-chemokine platelet factor 4 promotes monocyte survival and induces monocyte differentiation into macrophages. Blood 2000; 95: 1158-1166.
• 11 Cho HJ, Shashkin P, Gleissner CA. et al. Induction of dendritic cell-like phenotype in macrophages during foam cell formation. Physiol Genomics 2007; 29: 149-160.
• 12 Smith J, Trogan E, Ginsberg M. et al. Decreased atherosclerosis in mice deficient in both macrophage colony-stimulating factor (op) and apolipoprotein E. Proc Natl Acad Sci USA 1995; 92: 8264-8268.
• 13 Pervushina O, Scheuerer B, Reiling N. et al. Platelet factor 4/CXCL4 induces phagocytosis and the generation of reactive oxygen metabolites in mononuclear phagocytes independently of gi protein activation or intracellular calcium transients. J Immunol 2004; 173: 2060-2067.
• 14 Sachais BS, Kuo A, Nassar T, et al. Higazi AA. Platelet factor 4 binds to low-density lipoprotein receptors and disrupts the endocytic machinery, resulting in retention of low-density lipoprotein on the cell surface. Blood 2002; 99: 3613-3622.
• 15 Nassar T, Sachais BS, Akkawi S. et al. Platelet factor 4 enhances the binding of oxidized low-density lipoprotein to vascular wall cells. J Biol Chem 2003; 278: 6187-6193.
• 16 Lasagni L, Francalanci M, Annunziato F. et al. An alternatively spliced variant of CXCR3 mediates the inhibition of endothelial cell growth induced by IP-10, mig, and I-tac, and acts as functional receptor for platelet factor 4. J Exp Med 2003; 197: 1537-1549.
• 17 Petersen F, Bock L, Flad HD. et al. A chondroitin sulfate proteoglycan on human neutrophils specifically binds platelet factor 4 and is involved in cell activation. J Immunol 1998; 161: 4347-4355.